Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock

Allogene (Nasdaq: ALLO) intends to sell $175 million of common stock in an underwritten public offering announced April 13, 2026, with a 30-day underwriter option to purchase up to $26.25 million additional shares.

Rhea-AI Summary

Allogene (Nasdaq: ALLO) intends to sell $175 million of common stock in an underwritten public offering announced April 13, 2026, with a 30-day underwriter option to purchase up to $26.25 million additional shares. The offering is subject to market conditions and may not be completed.

Net proceeds are expected to fund general corporate purposes, including clinical trial and R&D expenses, general and administrative costs, and capital expenditures. Goldman Sachs, Jefferies and TD Cowen are joint book-running managers; TPG Capital BD is co-manager. Shares will be offered from a shelf registration declared effective April 25, 2024.

Positive

• Offering size of $175 million announced April 13, 2026
• Additional option for underwriters up to $26.25 million
• Proceeds earmarked for clinical trial and R&D spending

Negative

• Potential dilution to existing shareholders from primary share sale
• No assurance the offering will be completed or on proposed terms
• Market pressure possible if large share volume enters market

Argus Apr 14 session

-25.49% close to close Open Argus

Details

News Market Reaction – ALLO

On Apr 14, the first trading day after this news, ALLO closed 25.49% below the previous close.

Data tracked by StockTitan Argus for the Apr 14 session.

Key Figures

Proposed offering size: $175 million Underwriters’ option: $26.25 million Prior offering size: $110 million +5 more

Proposed offering size

$175 million

Common stock underwritten public offering

Underwriters’ option

$26.25 million

30-day option to purchase additional common shares

Prior offering size

$110 million

Common stock offering announced May 13, 2024

Shares in 2024 offering

37,931,035 shares

Common stock priced at $2.90 in May 2024

2024 offering price

$2.90 per share

Pricing for May 2024 common stock offering

MRD negativity (cema-cel)

58.3% (7/12 patients)

ALPHA3 interim Phase 2 results in LBCL cema-cel arm

MRD negativity (observation)

16.7% (2/12 patients)

Comparator arm in ALPHA3 interim analysis

Plasma ctDNA median change

97.7% decrease vs 26.6% increase

Day 45 median change, cema-cel vs observation arms

Previous Offering Reports

1 past event · Latest: May 13

Same Type 1 event

1. May 13

   Equity offering

   24h Move

   +2.1%

   Announced $110M common stock offering under shelf to fund AlloCAR T pipeline.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

underwritten public offering, joint book-running managers, co-manager, shelf registration statement, +2 more

6 terms

underwritten public offering financial

"it intends to offer and sell, in an underwritten public offering and subject to market"

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

joint book-running managers financial

"Goldman Sachs & Co. LLC, Jefferies and TD Cowen are acting as the joint book-running"

Joint book-running managers are the lead banks or financial firms responsible for organizing and overseeing the sale of a large financial offering, such as a company’s stock or bonds. They coordinate efforts to set the price, attract investors, and ensure the offering is successful. Their role is important to investors because they help ensure the offering is well-managed, properly priced, and accessible to a wide range of buyers.

co-manager financial

"TPG Capital BD, LLC is acting as co-manager for the offering."

A co-manager is one of several investment banks or brokerage firms that work together to sell a company's new stock or bond offering to investors. Think of them as teammates who help market, allocate and distribute the securities; their involvement can broaden buyer reach, share risk and affect how quickly and smoothly the offering is sold, which matters to investors because it can influence price stability and availability of shares or bonds.

shelf registration statement regulatory

"pursuant to a shelf registration statement filed by Allogene with the Securities"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

prospectus supplement regulatory

"A preliminary prospectus supplement related to the offering will be filed with the SEC"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

prospectus regulatory

"the preliminary prospectus supplement and the accompanying prospectus related to this"

A prospectus is a detailed document that explains a company's plans for offering new shares or investments to the public. It’s important because it provides potential investors with key information about the company’s business, risks, and how they might make money, helping them decide whether to invest. Think of it as a guidebook for understanding what you're buying into.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO) today announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, $175 million of shares of its common stock. All of the shares are being offered by Allogene. In addition, Allogene intends to grant the underwriters for the offering a 30-day option to purchase up to an additional $26.25 million of the shares of its common stock offered in the public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Allogene expects to use the net proceeds from this offering for general corporate purposes, which may include clinical trial expenses, research and development expenses, general and administrative expenses, and capital expenditures.

Goldman Sachs & Co. LLC, Jefferies and TD Cowen are acting as the joint book-running managers for the offering. TPG Capital BD, LLC is acting as co-manager for the offering.

The shares of common stock described above are being offered by Allogene pursuant to a shelf registration statement filed by Allogene with the Securities and Exchange Commission (SEC) that was declared effective on April 25, 2024. A preliminary prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus related to this offering, when available, may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, or by telephone at (866) 471-2526, or by email at prospectus-ny@ny.email.gs.com; or from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, or by telephone at (877) 821-7388, or by emailing prospectus_department@jefferies.com; or from TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at TDManualrequest@broadridge.com. 

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune disease. Led by cell therapy veterans applying proven CAR T experience, Allogene is developing a pipeline of off-the-shelf CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients.

Cautionary Note on Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. These statements may be identified by introductory words such as “may,” “expects,” “goal,” “intend,” “will,” “would,” “subject to” or words of similar meaning, or by the fact that they do not relate strictly to historical or current facts. Such forward-looking statements include statements regarding Allogene’s expectations with respect to the completion, timing and size of the proposed public offering, the use of proceeds from the offering and granting the underwriters a 30-day option to purchase additional shares. For such statements, Allogene claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Allogene’s expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed offering, and those factors disclosed in Allogene’s filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 12, 2026, and other filings that Allogene may make from time to time with the SEC. These forward-looking statements represent Allogene’s judgment as of the time of this release. Allogene disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Allogene Media/Investor Contact:
Christine Cassiano
EVP, Chief Corporate Affairs & Brand Strategy Officer
Christine.Cassiano@allogene.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Allogene (ALLO) announce on April 13, 2026 regarding a stock offering?

Allogene announced an underwritten offering of $175 million of common stock with a 30-day underwriter option for $26.25 million. According to the company, the offering is subject to market conditions and may not be completed as announced.

How will Allogene (ALLO) use the proceeds from the $175 million offering?

The company expects to use net proceeds for general corporate purposes, including clinical trial and R&D expenses, general and administrative costs, and capital expenditures. According to the company, specific allocations were not provided in the announcement.

Who are the underwriters for Allogene's (ALLO) April 2026 offering?

Goldman Sachs, Jefferies and TD Cowen are joint book-running managers, with TPG Capital BD as co-manager. According to the company, prospectus materials will be filed with the SEC and available when posted.

What does the underwriter option of $26.25 million mean for ALLO shareholders?

The 30-day option allows underwriters to buy up to $26.25 million additional shares, potentially increasing offered shares and diluting existing holders. According to the company, the option is standard and exercisable only if underwriters choose to purchase.

Will the Allogene (ALLO) offering definitely proceed and when will details be filed with the SEC?

There is no assurance the offering will proceed; it is subject to market and other conditions. According to the company, a preliminary prospectus supplement will be filed with the SEC and available on the SEC website when filed.

How might the $175 million offering affect Allogene's (ALLO) stock price short term?

A primary offering of this size can exert downward pressure if shares are sold into the market, increasing supply and potential dilution. According to the company, timing and terms are uncertain, which can also increase short-term volatility.